Moomoo AIのまとめ
On June 28, 2024, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed a Schedule 13G with the SEC, disclosing a 5.9% ownership stake in Recursion Pharmaceuticals, Inc. This stake amounts to 15,384,615 shares of Class A Common Stock. The filing indicates that RA Capital Management, L.P. serves as the investment adviser to the RA Capital Healthcare Fund, L.P., and may be deemed a beneficial owner of the securities held by the fund. The shares are reported based on the 260,812,291 shares of Class A Common Stock outstanding as of the closing of Recursion Pharmaceuticals' public offering. The Reporting Persons have disclaimed beneficial ownership of the reported securities except for the purpose of determining their obligations under Section 13(d) of the Act. The filing was completed on July 8, 2024, and includes a joint filing agreement among the Reporting Persons.
On June 28, 2024, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed a Schedule 13G with the SEC, disclosing a 5.9% ownership stake in Recursion Pharmaceuticals, Inc. This stake amounts to 15,384,615 shares of Class A Common Stock. The filing indicates that RA Capital Management, L.P. serves as the investment adviser to the RA Capital Healthcare Fund, L.P., and may be deemed a beneficial owner of the securities held by the fund. The shares are reported based on the 260,812,291 shares of Class A Common Stock outstanding as of the closing of Recursion Pharmaceuticals' public offering. The Reporting Persons have disclaimed beneficial ownership of the reported securities except for the purpose of determining their obligations under Section 13(d) of the Act. The filing was completed on July 8, 2024, and includes a joint filing agreement among the Reporting Persons.
2024年6月28日、RAキャピタル・マネジメント、LPは、Peter Kolchinsky、Rajeev Shah、RA Capital Healthcare Fund、LPとともに、レポート対象であるReport Personsとして、SECにスケジュール13Gを提出し、Recursion Pharmaceuticals、Inc.の5.9%の所有権を開示しました。この出資比率は、Class A Common Stockの15,384,615株に相当します。提出書類によれば、RAキャピタル・マネジメント、LPはRA Capital Healthcare Fund、LPの投資顧問として務め、フ...すべて展開
2024年6月28日、RAキャピタル・マネジメント、LPは、Peter Kolchinsky、Rajeev Shah、RA Capital Healthcare Fund、LPとともに、レポート対象であるReport Personsとして、SECにスケジュール13Gを提出し、Recursion Pharmaceuticals、Inc.の5.9%の所有権を開示しました。この出資比率は、Class A Common Stockの15,384,615株に相当します。提出書類によれば、RAキャピタル・マネジメント、LPはRA Capital Healthcare Fund、LPの投資顧問として務め、ファンドが保有する証券の有益所有者とみなされる可能性があります。これらの株式は、Recursion Pharmaceuticalsの公開オファリングが終了した時点での発行済みのClass A Common Stock 260,812,291株に基づいて報告されています。報告対象者は、13(d)条に基づく義務を決定する目的以外に、報告された証券の有益所有者であることを免責しています。この提出書類は2024年7月8日に完成し、レポート対象者間の共同申告契約が含まれています。
役に立った
役に立たない